“In a letter to the editor published in the Journal of Diabetes Science and Technology, David C. Klonoff, MD, medical director of the Diabetes Research Institute at Mills-Peninsula Medical Center in San Mateo, California, noted that the findings of the Hathaway study, based on a single tertiary care university eye clinic, “might not pertain to the general population.”
To assess the risk of NAION in patients prescribed semaglutide for diabetes or obesity, he performed a series of real-world analyses based on the electronic health record and claim dataset of Atropos Health, comprising 66 million people nationally.”